long intergenic non-protein coding RNA 2155Genealiases: []
Q-omics provides the consensus-scored LINC02155 profile across patient tissues and cancer cell-line models. LINC02155 expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, LINC02155 is differentially expressed in 1, with the highest sampling consensus in LUAD. Additionally, LINC02155 RNA expression shows 4,932 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight THCA, LUAD, and LSCC as cancer lineages where LINC02155 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02155 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02155 survival associations across molecular data types. LINC02155 RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02155 RNA expression–survival associations across cancer types. High LINC02155 expression shows unfavorable associations in THCA, KIRC, UCEC, LUAD and SARC, but favorable associations in GBM. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for LINC02155 RNA expression.
This table summarizes LINC02155 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02155. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02155 shows higher tumor expression in LUAD. The LUAD box plot shows higher LINC02155 RNA expression in tumor versus normal tissue (log2 FC = +0.073, t-test p = .040).
This table shows molecular features associated with LINC02155 in patient tissues and cancer cell lines. In patient samples, LINC02155 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
